Atlas Trials

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

Clinical trial NCT03558750 · TERMINATED

Trial details

NCT number
NCT03558750
Sponsor
Vanderbilt-Ingram Cancer Center
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Central Nervous System LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Central Nervous System LymphomaRefractory Diffuse Large B-Cell Lymphoma
Start date
2018-06-14
Primary completion
2019-04-16
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.